{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:03:15Z","timestamp":1788386595098,"version":"build-2803163510"},"reference-count":101,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","neurosurgery.theclinics.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurosurgery Clinics of North America"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.nec.2015.11.002","type":"journal-article","created":{"date-parts":[[2016,2,20]],"date-time":"2016-02-20T05:57:11Z","timestamp":1455947831000},"page":"249-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Medical Management of Meningiomas"],"prefix":"10.1016","volume":"27","author":[{"given":"Michael","family":"Karsy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Colman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy L.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.nec.2015.11.002_bib1","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.3171\/2011.2.FOCUS1116","article-title":"The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments","volume":"30","author":"Choy","year":"2011","journal-title":"Neurosurg Focus"},{"issue":"Suppl 2","key":"10.1016\/j.nec.2015.11.002_bib2","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/neuonc\/not151","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010","volume":"15","author":"Ostrom","year":"2013","journal-title":"Neuro Oncol"},{"issue":"6","key":"10.1016\/j.nec.2015.11.002_bib3","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1080\/02688690701684246","article-title":"Atypical meningiomas: WHO moved the goalposts?","volume":"21","author":"Smith","year":"2007","journal-title":"Br J Neurosurg"},{"issue":"6","key":"10.1016\/j.nec.2015.11.002_bib4","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.3171\/2013.10.FOCUS13341","article-title":"Recent developments in chemotherapy for meningiomas: a review","volume":"35","author":"Moazzam","year":"2013","journal-title":"Neurosurg Focus"},{"issue":"1","key":"10.1016\/j.nec.2015.11.002_bib5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/jnnp.20.1.22","article-title":"The recurrence of intracranial meningiomas after surgical treatment","volume":"20","author":"Simpson","year":"1957","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.nec.2015.11.002_bib6","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.wneu.2014.12.037","article-title":"The role of adjuvant radiotherapy after gross total resection of atypical meningiomas","volume":"83","author":"Hasan","year":"2015","journal-title":"World Neurosurg"},{"issue":"3","key":"10.1016\/j.nec.2015.11.002_bib7","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.3171\/2015.1.FOCUS14757","article-title":"An evidence-based treatment algorithm for the management of WHO grade II and III meningiomas","volume":"38","author":"Sun","year":"2015","journal-title":"Neurosurg Focus"},{"issue":"10","key":"10.1016\/j.nec.2015.11.002_bib8","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1212\/01.wnl.0000271382.62776.b7","article-title":"Recurrent meningioma: salvage therapy with long-acting somatostatin analogue","volume":"69","author":"Chamberlain","year":"2007","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.nec.2015.11.002_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nou148","article-title":"Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma","volume":"17","author":"Kaley","year":"2015","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.nec.2015.11.002_bib10","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/cncr.23803","article-title":"Interferon-alpha for\u00a0recurrent World Health Organization grade 1 intracranial meningiomas","volume":"113","author":"Chamberlain","year":"2008","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.nec.2015.11.002_bib11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/neuonc\/not330","article-title":"Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review","volume":"16","author":"Kaley","year":"2014","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.nec.2015.11.002_bib12","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.3171\/foc.2005.19.5.10","article-title":"Molecular genetics of meningiomas","volume":"19","author":"Ragel","year":"2005","journal-title":"Neurosurg Focus"},{"issue":"3","key":"10.1016\/j.nec.2015.11.002_bib13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7","article-title":"Merlin differentially associates with the microtubule and actin cytoskeleton","volume":"51","author":"Xu","year":"1998","journal-title":"J\u00a0Neurosci Res"},{"issue":"6","key":"10.1016\/j.nec.2015.11.002_bib14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2174\/138920310791824011","article-title":"Merlin, a \u201cmagic\u201d linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival","volume":"11","author":"Stamenkovic","year":"2010","journal-title":"Curr Protein Pept Sci"},{"issue":"8","key":"10.1016\/j.nec.2015.11.002_bib15","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/hmg\/3.8.1393","article-title":"Characterization of a new member of the human beta-adaptin gene family from chromosome 22q12, a candidate meningioma gene","volume":"3","author":"Peyrard","year":"1994","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.nec.2015.11.002_bib16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1054\/bjoc.2000.1583","article-title":"INI1 mutations in meningiomas at a potential hotspot in exon 9","volume":"84","author":"Schmitz","year":"2001","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.nec.2015.11.002_bib17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11060-010-0342-2","article-title":"Pathological classification and molecular genetics of meningiomas","volume":"99","author":"Mawrin","year":"2010","journal-title":"J\u00a0Neurooncol"},{"issue":"10","key":"10.1016\/j.nec.2015.11.002_bib18","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1158\/0008-5472.CAN-05-1628","article-title":"Protein 4.1B\/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating rac1-dependent c-Jun-NH(2)-kinase signaling","volume":"66","author":"Gerber","year":"2006","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.nec.2015.11.002_bib19","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1158\/1078-0432.CCR-04-2550","article-title":"Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas","volume":"11","author":"Mawrin","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.nec.2015.11.002_bib20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng.2526","article-title":"Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations","volume":"45","author":"Brastianos","year":"2013","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.nec.2015.11.002_bib21","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s13277-013-0800-5","article-title":"Targeting the PI3K\/AKT\/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding","volume":"34","author":"Sami","year":"2013","journal-title":"Tumour Biol"},{"issue":"3","key":"10.1016\/j.nec.2015.11.002_bib22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11060-010-0381-8","article-title":"Aberrant signaling pathways in meningiomas","volume":"99","author":"Ragel","year":"2010","journal-title":"J\u00a0Neurooncol"},{"issue":"1","key":"10.1016\/j.nec.2015.11.002_bib23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/14728222.2011.645805","article-title":"Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy","volume":"16","author":"Santarpia","year":"2012","journal-title":"Expert Opin Ther Targets"},{"issue":"2","key":"10.1016\/j.nec.2015.11.002_bib24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11060-010-0399-y","article-title":"Analysis of transforming growth factor \u03b2 receptor expression and signaling in higher grade meningiomas","volume":"103","author":"Johnson","year":"2011","journal-title":"J\u00a0Neurooncol"},{"issue":"Suppl","key":"10.1016\/j.nec.2015.11.002_bib25","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/j.semcancer.2015.03.007","article-title":"Therapeutic targeting of replicative immortality","volume":"35","author":"Yaswen","year":"2015","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"10.1016\/j.nec.2015.11.002_bib26","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0002-9440(10)61737-3","article-title":"Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas","volume":"159","author":"Bostrom","year":"2001","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.nec.2015.11.002_bib27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"7\u20138","key":"10.1016\/j.nec.2015.11.002_bib28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2119\/molmed.2010.00005","article-title":"Gene expression profiling of the hedgehog signaling pathway in human meningiomas","volume":"16","author":"Laurendeau","year":"2010","journal-title":"Mol Med"},{"issue":"6","key":"10.1016\/j.nec.2015.11.002_bib29","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1593\/neo.08356","article-title":"Notch activation is associated with tetraploidy and enhanced chromosomal instability in meningiomas","volume":"10","author":"Baia","year":"2008","journal-title":"Neoplasia"},{"issue":"5","key":"10.1016\/j.nec.2015.11.002_bib30","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00432-009-0708-z","article-title":"Genetic and protein changes of E-cadherin in meningiomas","volume":"136","author":"Pecina-Slaus","year":"2010","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"6123","key":"10.1016\/j.nec.2015.11.002_bib31","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science"},{"issue":"14","key":"10.1016\/j.nec.2015.11.002_bib32","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1038\/onc.2014.120","article-title":"miR-200a-mediated suppression of non-muscle heavy chain IIb inhibits meningioma cell migration and tumor growth in\u00a0vivo","volume":"34","author":"Senol","year":"2015","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.nec.2015.11.002_bib33","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.bbrc.2015.03.038","article-title":"MicroRNA-224 targets ERG2 and contributes to malignant progressions of meningioma","volume":"460","author":"Wang","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"10.1016\/j.nec.2015.11.002_bib34","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/neuonc\/nov014","article-title":"Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAs","volume":"17","author":"Ludwig","year":"2015","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.nec.2015.11.002_bib35","first-page":"1189","article-title":"Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors","volume":"55","author":"Samoto","year":"1995","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.nec.2015.11.002_bib36","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4103\/0377-4929.125286","article-title":"Vascular endothelial growth factor expression and angiogenesis in various grades and subtypes of meningioma","volume":"56","author":"Dharmalingam","year":"2013","journal-title":"Indian J Pathol Microbiol"},{"issue":"4","key":"10.1016\/j.nec.2015.11.002_bib37","first-page":"938","article-title":"Vascular endothelial growth factor, hepatocyte growth factor\/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy","volume":"46","author":"Lamszus","year":"2000","journal-title":"Neurosurgery"},{"issue":"2","key":"10.1016\/j.nec.2015.11.002_bib38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11060-014-1503-5","article-title":"Hypoxia inducible factor-1 is involved in growth factor, glucocorticoid and hypoxia mediated regulation of vascular endothelial growth factor-A in human meningiomas","volume":"119","author":"Wu","year":"2014","journal-title":"J\u00a0Neurooncol"},{"issue":"3","key":"10.1016\/j.nec.2015.11.002_bib39","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.4238\/vol10-3gmr1212","article-title":"Expression of aquaporin-4 in human supratentorial meningiomas with peritumoral brain edema and correlation of VEGF with edema formation","volume":"10","author":"Wang","year":"2011","journal-title":"Genet Mol Res"},{"issue":"2","key":"10.1016\/j.nec.2015.11.002_bib40","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00066-010-2184-4","article-title":"Bevacizumab as a treatment option for radiation-induced cerebral necrosis","volume":"187","author":"Matuschek","year":"2011","journal-title":"Strahlenther Onkol"},{"issue":"12","key":"10.1016\/j.nec.2015.11.002_bib41","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/annonc\/mdq634","article-title":"Bevacizumab-induced regression of anaplastic meningioma","volume":"21","author":"Puchner","year":"2010","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.nec.2015.11.002_bib42","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/annonc\/mdr012","article-title":"Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab","volume":"22","author":"Goutagny","year":"2011","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.nec.2015.11.002_bib43","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jocn.2011.07.024","article-title":"Regression of a meningioma during paclitaxel and bevacizumab therapy for breast cancer","volume":"19","author":"Wilson","year":"2012","journal-title":"J\u00a0Clin Neurosci"},{"issue":"1","key":"10.1016\/j.nec.2015.11.002_bib44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11060-012-0861-0","article-title":"Bevacizumab therapy for adults with recurrent\/progressive meningioma: a retrospective series","volume":"109","author":"Lou","year":"2012","journal-title":"J\u00a0Neurooncol"},{"issue":"1","key":"10.1016\/j.nec.2015.11.002_bib45","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11060-012-0886-4","article-title":"Atypical and anaplastic meningiomas treated with bevacizumab","volume":"109","author":"Nayak","year":"2012","journal-title":"J\u00a0Neurooncol"},{"issue":"3","key":"10.1016\/j.nec.2015.11.002_bib46","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1055\/s-0033-1338262","article-title":"Antiangiogenic agents for nonmalignant brain tumors","volume":"74","author":"Hawasli","year":"2013","journal-title":"J\u00a0Neurol Surg B Skull Base"},{"issue":"3","key":"10.1016\/j.nec.2015.11.002_bib47","doi-asserted-by":"crossref","first-page":"e59941","DOI":"10.1371\/journal.pone.0059941","article-title":"Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients","volume":"8","author":"Nunes","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.nec.2015.11.002_bib48","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-014-1358-9","article-title":"A\u00a0phase II trial of PTK787\/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas","volume":"117","author":"Raizer","year":"2014","journal-title":"J\u00a0Neurooncol"},{"issue":"6","key":"10.1016\/j.nec.2015.11.002_bib49","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1215\/15228517-2009-010","article-title":"Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)","volume":"11","author":"Wen","year":"2009","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.nec.2015.11.002_bib50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/neuonc\/nop017","article-title":"A\u00a0phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas","volume":"12","author":"Raizer","year":"2010","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.nec.2015.11.002_bib51","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-009-9948-7","article-title":"Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma","volume":"96","author":"Norden","year":"2010","journal-title":"J\u00a0Neurooncol"},{"issue":"5","key":"10.1016\/j.nec.2015.11.002_bib52","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3171\/jns.1997.86.5.0840","article-title":"Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea","volume":"86","author":"Schrell","year":"1997","journal-title":"J\u00a0Neurosurg"},{"issue":"2","key":"10.1016\/j.nec.2015.11.002_bib53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1023\/A:1026770624783","article-title":"Hydroxyurea chemotherapy for unresectable or residual meningioma","volume":"49","author":"Newton","year":"2000","journal-title":"J\u00a0Neurooncol"},{"issue":"2","key":"10.1016\/j.nec.2015.11.002_bib54","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3171\/jns.2002.97.2.0341","article-title":"Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma","volume":"97","author":"Mason","year":"2002","journal-title":"J\u00a0Neurosurg"},{"issue":"2","key":"10.1016\/j.nec.2015.11.002_bib55","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1054\/jocn.2001.1019","article-title":"Treatment of high risk or recurrent meningiomas with hydroxyurea","volume":"9","author":"Rosenthal","year":"2002","journal-title":"J\u00a0Clin Neurosci"},{"issue":"1\u20132","key":"10.1016\/j.nec.2015.11.002_bib56","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/B:NEON.0000021827.85754.8e","article-title":"Non-resectable slow-growing meningiomas treated by hydroxyurea","volume":"67","author":"Loven","year":"2004","journal-title":"J\u00a0Neurooncol"},{"issue":"2","key":"10.1016\/j.nec.2015.11.002_bib57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11060-004-2337-3","article-title":"Prolonged oral hydroxyurea and concurrent 3D-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study","volume":"74","author":"Hahn","year":"2005","journal-title":"J\u00a0Neurooncol"},{"issue":"3","key":"10.1016\/j.nec.2015.11.002_bib58","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1055\/s-2006-949518","article-title":"Hydroxyurea treatment of meningiomas: a pilot study","volume":"16","author":"Weston","year":"2006","journal-title":"Skull Base"},{"issue":"3","key":"10.1016\/j.nec.2015.11.002_bib59","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s11060-011-0541-5","article-title":"Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series","volume":"104","author":"Chamberlain","year":"2011","journal-title":"J\u00a0Neurooncol"},{"issue":"2","key":"10.1016\/j.nec.2015.11.002_bib60","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11060-011-0741-z","article-title":"Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma","volume":"107","author":"Chamberlain","year":"2012","journal-title":"J\u00a0Neurooncol"},{"issue":"2","key":"10.1016\/j.nec.2015.11.002_bib61","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-011-0687-1","article-title":"Phase II study of Gleevec(R) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma","volume":"106","author":"Reardon","year":"2012","journal-title":"J\u00a0Neurooncol"},{"issue":"6","key":"10.1016\/j.nec.2015.11.002_bib62","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3340\/jkns.2012.52.6.517","article-title":"Long-term follow-up result of hydroxyurea chemotherapy for recurrent meningiomas","volume":"52","author":"Kim","year":"2012","journal-title":"J\u00a0Korean Neurosurg Soc"},{"issue":"5","key":"10.1016\/j.nec.2015.11.002_bib63","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1227\/01.NEU.0000245597.46581.FB","article-title":"Calcium channel antagonists augment hydroxyurea- and RU486-induced inhibition of meningioma growth in\u00a0vivo and in\u00a0vitro","volume":"59","author":"Ragel","year":"2006","journal-title":"Neurosurgery"},{"issue":"4","key":"10.1016\/j.nec.2015.11.002_bib64","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.3171\/FOC-07\/10\/E10","article-title":"Chronic suppressive therapy with calcium channel antagonists for refractory meningiomas","volume":"23","author":"Ragel","year":"2007","journal-title":"Neurosurg Focus"},{"issue":"3","key":"10.1016\/j.nec.2015.11.002_bib65","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/00006123-200003000-00032","article-title":"Calcium channel antagonist effect on in\u00a0vitro meningioma signal transduction pathways after growth factor stimulation","volume":"46","author":"Jensen","year":"2000","journal-title":"Neurosurgery"},{"issue":"3","key":"10.1016\/j.nec.2015.11.002_bib66","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3171\/jns.1987.66.3.0405","article-title":"Correlation of meningioma hormone receptor status with hormone sensitivity in a tumor stem-cell assay","volume":"66","author":"Grunberg","year":"1987","journal-title":"J\u00a0Neurosurg"},{"issue":"1","key":"10.1016\/j.nec.2015.11.002_bib67","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00182088","article-title":"Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma","volume":"8","author":"Grunberg","year":"1990","journal-title":"J\u00a0Neurooncol"},{"issue":"1\u20132","key":"10.1016\/j.nec.2015.11.002_bib68","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF01809555","article-title":"Hormone treatment of meningiomas: lack of response to medroxyprogesterone acetate (MPA). A pilot study of five cases","volume":"80","author":"Jaaskelainen","year":"1986","journal-title":"Acta Neurochir (Wien)"},{"issue":"6","key":"10.1016\/j.nec.2015.11.002_bib69","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3171\/jns.1991.74.6.0861","article-title":"Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone","volume":"74","author":"Grunberg","year":"1991","journal-title":"J\u00a0Neurosurg"},{"issue":"8","key":"10.1016\/j.nec.2015.11.002_bib70","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/07357900601062339","article-title":"Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma","volume":"24","author":"Grunberg","year":"2006","journal-title":"Cancer Invest"},{"issue":"10","key":"10.1016\/j.nec.2015.11.002_bib71","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00701-014-2188-4","article-title":"Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486)","volume":"156","author":"Touat","year":"2014","journal-title":"Acta Neurochir (Wien)"},{"issue":"6","key":"10.1016\/j.nec.2015.11.002_bib72","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/jnnp.55.6.486","article-title":"Mifepristone (RU 486) treatment of meningiomas","volume":"55","author":"Lamberts","year":"1992","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"9","key":"10.1016\/j.nec.2015.11.002_bib73","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/sj.eye.6701370","article-title":"Mifepristone treatment in patients with surgically incurable sphenoid-ridge meningioma: a long-term follow-up","volume":"18","author":"de Keizer","year":"2004","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.nec.2015.11.002_bib74","doi-asserted-by":"crossref","first-page":"267831","DOI":"10.1155\/2015\/267831","article-title":"The role of mifepristone in meningiomas management: a systematic review of the literature","volume":"2015","author":"Cossu","year":"2015","journal-title":"Biomed Res Int"},{"issue":"3","key":"10.1016\/j.nec.2015.11.002_bib75","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0090-3019(85)90030-8","article-title":"Antiestrogenic therapy of meningiomas\u2013a pilot study","volume":"24","author":"Markwalder","year":"1985","journal-title":"Surg Neurol"},{"issue":"1","key":"10.1016\/j.nec.2015.11.002_bib76","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01050266","article-title":"A\u00a0phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study","volume":"15","author":"Goodwin","year":"1993","journal-title":"J\u00a0Neurooncol"},{"issue":"1","key":"10.1016\/j.nec.2015.11.002_bib77","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/CEJ.0000000000000133","article-title":"Association of tamoxifen with meningioma: a population-based study in Sweden","volume":"25","author":"Ji","year":"2016","journal-title":"Eur J Cancer Prev"},{"issue":"5","key":"10.1016\/j.nec.2015.11.002_bib78","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3171\/jns.1996.84.5.0733","article-title":"Adjuvant combined modality therapy for malignant meningiomas","volume":"84","author":"Chamberlain","year":"1996","journal-title":"J\u00a0Neurosurg"},{"issue":"7","key":"10.1016\/j.nec.2015.11.002_bib79","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1212\/01.WNL.0000118300.82017.F4","article-title":"Temozolomide for treatment-resistant recurrent meningioma","volume":"62","author":"Chamberlain","year":"2004","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.nec.2015.11.002_bib80","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11060-005-9093-x","article-title":"Salvage chemotherapy with CPT-11 for recurrent meningioma","volume":"78","author":"Chamberlain","year":"2006","journal-title":"J\u00a0Neurooncol"},{"issue":"3","key":"10.1016\/j.nec.2015.11.002_bib81","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3171\/jns.2007.106.3.455","article-title":"Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas","volume":"106","author":"Gupta","year":"2007","journal-title":"J\u00a0Neurosurg"},{"issue":"20","key":"10.1016\/j.nec.2015.11.002_bib82","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1002\/cncr.27460","article-title":"Trabectedin has promising antineoplastic activity in high-grade meningioma","volume":"118","author":"Preusser","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.nec.2015.11.002_bib83","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.suronc.2015.06.004","article-title":"In\u00a0vitro testing to a panel of potential chemotherapeutics and current concepts of chemotherapy in benign meningiomas","volume":"24","author":"Balik","year":"2015","journal-title":"Surg Oncol"},{"issue":"8646","key":"10.1016\/j.nec.2015.11.002_bib84","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0140-6736(89)92465-3","article-title":"Successful treatment of meningioma with octreotide","volume":"1","author":"Runzi","year":"1989","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.nec.2015.11.002_bib85","first-page":"237","article-title":"Clinical use of octreotide in unresectable meningiomas. A report of three cases","volume":"37","author":"Garcia-Luna","year":"1993","journal-title":"J\u00a0Neurosurg Sci"},{"issue":"1","key":"10.1016\/j.nec.2015.11.002_bib86","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0303-8467(97)00110-8","article-title":"Visual improvement during octreotide therapy in a case of episellar meningioma","volume":"100","author":"Jaffrain-Rea","year":"1998","journal-title":"Clin Neurol Neurosurg"},{"issue":"5","key":"10.1016\/j.nec.2015.11.002_bib87","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/neuonc\/nor044","article-title":"Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma","volume":"13","author":"Johnson","year":"2011","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.nec.2015.11.002_bib88","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00280-014-2422-z","article-title":"Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy","volume":"73","author":"Simo","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.nec.2015.11.002_bib89","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1212\/WNL.0000000000001153","article-title":"Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma","volume":"84","author":"Norden","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.nec.2015.11.002_bib90","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11060-015-1812-3","article-title":"Combined treatment by octreotide and everolimus: octreotide enhances inhibitory effect of everolimus in aggressive meningiomas","volume":"124","author":"Graillon","year":"2015","journal-title":"J\u00a0Neurooncol"},{"issue":"2","key":"10.1016\/j.nec.2015.11.002_bib91","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00006123-199702000-00007","article-title":"The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B","volume":"40","author":"Kaba","year":"1997","journal-title":"Neurosurgery"},{"issue":"8","key":"10.1016\/j.nec.2015.11.002_bib92","first-page":"2269","article-title":"Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography","volume":"7","author":"Muhr","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.nec.2015.11.002_bib93","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2217\/cns.13.17","article-title":"IFN-\u03b1 for recurrent surgery- and radiation-refractory high-grade meningioma: a retrospective case series","volume":"2","author":"Chamberlain","year":"2013","journal-title":"CNS Oncol"},{"issue":"1","key":"10.1016\/j.nec.2015.11.002_bib94","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3171\/jns.1999.91.1.0093","article-title":"Growth hormone receptor expression and function in meningiomas: effect of a specific receptor antagonist","volume":"91","author":"Friend","year":"1999","journal-title":"J\u00a0Neurosurg"},{"issue":"3","key":"10.1016\/j.nec.2015.11.002_bib95","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3171\/jns.2001.94.3.0487","article-title":"Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice","volume":"94","author":"McCutcheon","year":"2001","journal-title":"J\u00a0Neurosurg"},{"issue":"12","key":"10.1016\/j.nec.2015.11.002_bib96","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.18632\/oncotarget.3692","article-title":"Valproic acid promotes radiosensitization in meningioma stem-like cells","volume":"6","author":"Chiou","year":"2015","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.nec.2015.11.002_bib97","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/NEN.0000000000000129","article-title":"Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex","volume":"73","author":"Koschny","year":"2014","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"issue":"5","key":"10.1016\/j.nec.2015.11.002_bib98","doi-asserted-by":"crossref","first-page":"9936","DOI":"10.3390\/ijms16059936","article-title":"Aminolevulinic acid-mediated photodynamic therapy of human meningioma: an in\u00a0vitro study on primary cell lines","volume":"16","author":"El-Khatib","year":"2015","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.nec.2015.11.002_bib99","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.nec.2015.11.002_bib100","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.nec.2015.11.002_bib101","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.18632\/oncotarget.3082","article-title":"Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma","volume":"6","author":"Du","year":"2015","journal-title":"Oncotarget"}],"container-title":["Neurosurgery Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1042368015001163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1042368015001163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T16:33:13Z","timestamp":1567614793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1042368015001163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S1042368015001163"],"URL":"https:\/\/doi.org\/10.1016\/j.nec.2015.11.002","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726464581.793544884","asserted-by":"object"}]},"ISSN":["1042-3680"],"issn-type":[{"value":"1042-3680","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Management of Meningiomas","name":"articletitle","label":"Article Title"},{"value":"Neurosurgery Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nec.2015.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}